| 标题 |
 Abstract GS3-01: Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer |
| 网址 | |
| DOI |
10.1158/1538-7445.sabcs20-gs3-01
doi
|
| 其它 |
期刊：Cancer Research 作者：Hope S. Rugo; Peter Schmid; David W. Cescon; Zbigniew Nowecki; Seock-Ah Im; et al 出版日期：2021-02-15 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)
DIVINEDC
拆迁办禁言
渡人舟
Criminology34
极限001
Enigma_GEB
cdercder
GingerF
Nole
DW
Juice
null
无极微光
Lingeek
草珊瑚
七听
Kao
祝风华
76ers
谷雷努
皖公网安备34019202002308
